These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7930703)

  • 21. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
    van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
    J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
    Rezza G; Galai N; Pezzotti P; Vlahov D; Graham NM; Viale P; Angarano G
    Antivir Ther; 1997 Jul; 2(3):167-74. PubMed ID: 11322271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined therapy with zidovudine, recombinant granulocyte colony stimulating factors and erythropoietin in asymptomatic HIV patients.
    Perrella O; Finelli E; Perrella A; Tartaglia G; Scognamiglio P; Scalera G
    J Chemother; 1996 Feb; 8(1):63-6. PubMed ID: 8835112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam.
    Bindels PJ; Krol A; Roos M; Veenstra J; van den Hoek JA; Miedema F; Coutinho RA
    J Infect Dis; 1995 Jul; 172(1):97-104. PubMed ID: 7797949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of short-term efficacy of N-acetyl-L-cysteine in human immunodeficiency virus-positive patients with CD4 cell counts < 250/mm3.
    Clotet B; Gomez M; Ruiz L; Sirera G; Romeu J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):98-9. PubMed ID: 7712240
    [No Abstract]   [Full Text] [Related]  

  • 26. [Syncitia inducing phenotype, zidovudine++ resistance and fast clinical progression in a child infected by HIV].
    Mellado Peña MJ; Villota Arrieta J; Bernal Zamora A; Cilleruelo Ortega MJ; García López M; Barreiro Casal G; Pérez Jurado ML; Martín Fontelos P
    An Esp Pediatr; 1997 Jan; 46(1):65-8. PubMed ID: 9082891
    [No Abstract]   [Full Text] [Related]  

  • 27. Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion.
    Vogel M; Lichterfeld M; Kaufmann DE; Mui SK; Altfeld M; Voigt E; Ahlenstiel G; Kupfer B; Walker B; Spengler U; Rockstroh JK
    Eur J Med Res; 2006 Jul; 11(7):273-8. PubMed ID: 16899420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 sensitivity to zidovudine and clinical outcome.
    Maxeiner HG; Habermehl KO; Grünewald T; Ruf B
    Lancet; 1992 Mar; 339(8793):626-7. PubMed ID: 1347139
    [No Abstract]   [Full Text] [Related]  

  • 29. Concorde remains aloft.
    Lancet; 1989 Oct; 2(8670):1017-8. PubMed ID: 2572744
    [No Abstract]   [Full Text] [Related]  

  • 30. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group.
    Koch MA; Volberding PA; Lagakos SW; Booth DK; Pettinelli C; Myers MW
    Arch Intern Med; 1992 Nov; 152(11):2286-92. PubMed ID: 1359846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Killing of primary CD4+ T cells by non-syncytium-inducing macrophage-tropic human immunodeficiency virus type 1.
    Yu X; McLane MF; Ratner L; O'Brien W; Collman R; Essex M; Lee TH
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):10237-41. PubMed ID: 7937869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children.
    Spencer LT; Ogino MT; Dankner WM; Spector SA
    J Infect Dis; 1994 Mar; 169(3):491-5. PubMed ID: 7908924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment failure of preventive zidovudine in maternal fetal transmission of HIV].
    Wirtgen P; Pons JC; Boubon MC; Taburet AM; Delfraissy JF; Horovitz J
    J Gynecol Obstet Biol Reprod (Paris); 1993; 22(3):289-92. PubMed ID: 8102148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection.
    Margolick JB; Muñoz A; Vlahov D; Solomon L; Astemborski J; Cohn S; Nelson KE
    JAMA; 1992 Mar; 267(12):1631-6. PubMed ID: 1347321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of zidovudine on progression to AIDS in cohort studies.
    Schechter MT; Craib KJ; Le TN; Montaner JS; McLeod WA; Willoughby B; Elmslie KD; O'Shaughnessy MV
    Lancet; 1989 May; 1(8645):1026-7. PubMed ID: 2565507
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of the HIV-infected patient.
    Bryan CS; Postic B
    J S C Med Assoc; 1988 Sep; 84(9):437-43. PubMed ID: 2903271
    [No Abstract]   [Full Text] [Related]  

  • 37. Quantitation of human immunodeficiency virus (HIV) with respect to disease stage and zidovudine (AZT) therapy.
    Ved Brat SS; Shepherd LP; Boulberhane A; Pierce PF; Hellman KB
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1271-81. PubMed ID: 1520539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early identification of human immunodeficiency virus-infected asymptomatic subjects susceptible to zidovudine by quantitative viral coculture and reverse transcription-linked polymerase chain reaction.
    Lu W; Andrieu JM
    J Infect Dis; 1993 May; 167(5):1014-20. PubMed ID: 7683705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy.
    Hamed KA; Winters MA; Holodniy M; Katzenstein DA; Merigan TC
    J Infect Dis; 1993 Apr; 167(4):798-802. PubMed ID: 8450243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease.
    Salerno-Gonçalves R; Lu W; Andrieu JM
    J Virol; 2000 Jul; 74(14):6648-51. PubMed ID: 10864680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.